First Time Loading...

Axonics Inc
NASDAQ:AXNX

Watchlist Manager
Axonics Inc Logo
Axonics Inc
NASDAQ:AXNX
Watchlist
Price: 67.13 USD -0.07%
Updated: Jun 7, 2024

Intrinsic Value

Axonics, Inc. is a medical device company, which engages in developing and commercializing of novel implantable sacral neuromodulation (SNM) devices to treat patients with bladder and bowel dysfunctio... [ Read More ]

The intrinsic value of one AXNX stock under the Base Case scenario is 26.72 USD. Compared to the current market price of 67.13 USD, Axonics Inc is Overvalued by 60%.

Key Points:
AXNX Intrinsic Value
Base Case
26.72 USD
Overvaluation 60%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Axonics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling AXNX stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Ask me anything about
Axonics Inc

Provide an overview of the primary business activities
of Axonics Inc.

What unique competitive advantages
does Axonics Inc hold over its rivals?

What risks and challenges
does Axonics Inc face in the near future?

Has there been any significant insider trading activity
in Axonics Inc recently?

Summarize the latest earnings call
of Axonics Inc.

What significant events have occurred
in Axonics Inc over the past months?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Axonics Inc.

Provide P/S
for Axonics Inc.

Provide P/E
for Axonics Inc.

Provide P/OCF
for Axonics Inc.

Provide P/FCFE
for Axonics Inc.

Provide P/B
for Axonics Inc.

Provide EV/S
for Axonics Inc.

Provide EV/GP
for Axonics Inc.

Provide EV/EBITDA
for Axonics Inc.

Provide EV/EBIT
for Axonics Inc.

Provide EV/OCF
for Axonics Inc.

Provide EV/FCFF
for Axonics Inc.

Provide EV/IC
for Axonics Inc.

Show me price targets
for Axonics Inc made by professional analysts.

What are the Revenue projections
for Axonics Inc?

How accurate were the past Revenue estimates
for Axonics Inc?

What are the Net Income projections
for Axonics Inc?

How accurate were the past Net Income estimates
for Axonics Inc?

What are the EPS projections
for Axonics Inc?

How accurate were the past EPS estimates
for Axonics Inc?

What are the EBIT projections
for Axonics Inc?

How accurate were the past EBIT estimates
for Axonics Inc?

Compare the revenue forecasts
for Axonics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Axonics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Axonics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Axonics Inc compared to its peers.

Compare the P/E ratios
of Axonics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Axonics Inc with its peers.

Analyze the financial leverage
of Axonics Inc compared to its main competitors.

Show all profitability ratios
for Axonics Inc.

Provide ROE
for Axonics Inc.

Provide ROA
for Axonics Inc.

Provide ROIC
for Axonics Inc.

Provide ROCE
for Axonics Inc.

Provide Gross Margin
for Axonics Inc.

Provide Operating Margin
for Axonics Inc.

Provide Net Margin
for Axonics Inc.

Provide FCF Margin
for Axonics Inc.

Show all solvency ratios
for Axonics Inc.

Provide D/E Ratio
for Axonics Inc.

Provide D/A Ratio
for Axonics Inc.

Provide Interest Coverage Ratio
for Axonics Inc.

Provide Altman Z-Score Ratio
for Axonics Inc.

Provide Quick Ratio
for Axonics Inc.

Provide Current Ratio
for Axonics Inc.

Provide Cash Ratio
for Axonics Inc.

What is the historical Revenue growth
over the last 5 years for Axonics Inc?

What is the historical Net Income growth
over the last 5 years for Axonics Inc?

What is the current Free Cash Flow
of Axonics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Axonics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Axonics Inc

Current Assets 482m
Cash & Short-Term Investments 332.8m
Receivables 50.5m
Other Current Assets 98.7m
Non-Current Assets 233.5m
PP&E 38.9m
Intangibles 177m
Other Non-Current Assets 17.6m
Current Liabilities 48.4m
Accounts Payable 15.8m
Accrued Liabilities 32.6m
Non-Current Liabilities 40.1m
Other Non-Current Liabilities 40.1m
Efficiency

Earnings Waterfall
Axonics Inc

Revenue
387.1m USD
Cost of Revenue
-95.8m USD
Gross Profit
291.3m USD
Operating Expenses
-298.8m USD
Operating Income
-7.5m USD
Other Expenses
-8.5m USD
Net Income
-15.9m USD

Free Cash Flow Analysis
Axonics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

AXNX Profitability Score
Profitability Due Diligence

Axonics Inc's profitability score is 40/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional 3-Years Revenue Growth
ROE is Increasing
ROIC is Increasing
40/100
Profitability
Score

Axonics Inc's profitability score is 40/100. The higher the profitability score, the more profitable the company is.

AXNX Solvency Score
Solvency Due Diligence

Axonics Inc's solvency score is 69/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
69/100
Solvency
Score

Axonics Inc's solvency score is 69/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

AXNX Price Targets Summary
Axonics Inc

Wall Street analysts forecast AXNX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AXNX is 73.16 USD with a low forecast of 71.71 USD and a high forecast of 78.75 USD.

Lowest
Price Target
71.71 USD
7% Upside
Average
Price Target
73.16 USD
9% Upside
Highest
Price Target
78.75 USD
17% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

AXNX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

AXNX Price
Axonics Inc

1M 1M
0%
6M 6M
+16%
1Y 1Y
+32%
3Y 3Y
+13%
5Y 5Y
+113%
10Y 10Y
+348%
Annual Price Range
67.13
52w Low
47.99
52w High
69.65
Price Metrics
Average Annual Return 21.71%
Standard Deviation of Annual Returns 40.13%
Max Drawdown -61%
Shares Statistics
Market Capitalization 3.4B USD
Shares Outstanding 51 018 500
Percentage of Shares Shorted 7.95%

AXNX Return Decomposition
Main factors of price return

What is price return decomposition?

AXNX News

Other Videos

Last Important Events
Axonics Inc

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Axonics Inc

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Axonics Inc Logo
Axonics Inc

Country

United States of America

Industry

Health Care

Market Cap

3.4B USD

Dividend Yield

0%

Description

Axonics, Inc. is a medical device company, which engages in developing and commercializing of novel implantable sacral neuromodulation (SNM) devices to treat patients with bladder and bowel dysfunction. The company is headquartered in Irvine, California and currently employs 517 full-time employees. The company went IPO on 2018-10-31. The company is engaged in developing and commercializing products for patients with bladder and bowel dysfunction. The bladder and bowel dysfunction includes implantable sacral neuromodulation (SNM) systems to treat urinary urge incontinence (UUI) and urinary urgency frequency (UUF), together referred to as overactive bladder (OAB), as well as fecal incontinence (FI), and non-obstructive urinary retention (UR), and a urethral bulking agent to treat female stress urinary incontinence (SUI). The company has designed and developed the rechargeable sacral neuromodulation (SNM) system (r-SNM System), which delivers mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company has two relating to its r-SNM System, a European study, RELAX-OAB, and a United States pivotal study, ARTISAN-SNM. The company offers urethral bulking agent, Bulkamid for stress urinary incontinence.

Contact

CALIFORNIA
Irvine
26 Technology Dr
+19493966322.0
https://www.axonics.com/

IPO

2018-10-31

Employees

517

Officers

CEO & Director
Mr. Raymond W. Cohen
Chief Operating Officer
Mr. Rinda K. Sama
Executive VP, Chief Marketing & Strategy Officer
Dr. John Woock Ph.D.
Chief Commercial Officer
Mr. Alfred J. Ford Jr.
Chief Financial Officer
Ms. Kari Keese
Chief Technology Officer
Mr. Guangqiang Jiang Ph.D.
Show More
Vice President of Investor Relations
Mr. Neil Bhalodkar
General Counsel & Chief Compliance Officer
Mr. Aaron Pettit
Senior VP, General & IP Counsel
Mr. Michael V. Williamson Esq., J.D.
Chief Medical Officer
Dr. Karen L. Noblett M.A.S., M.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one AXNX stock?

The intrinsic value of one AXNX stock under the Base Case scenario is 26.72 USD.

Is AXNX stock undervalued or overvalued?

Compared to the current market price of 67.13 USD, Axonics Inc is Overvalued by 60%.